Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

7.7%

1 terminated out of 13 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed with results

Key Signals

4 with results67% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (1)
Early P 1 (1)
P 1 (4)
P 2 (5)
P 3 (1)

Trial Status

Recruiting5
Active Not Recruiting2
Completed2
Not Yet Recruiting2
Terminated1
Withdrawn1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06532279Phase 2Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT07441681Phase 3Not Yet Recruiting

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

NCT07195734Phase 2Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

NCT05172245Phase 1Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

NCT03010150Recruiting

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

NCT05232851Phase 1Active Not Recruiting

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT04533750Phase 1Active Not Recruiting

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT07156227Phase 1Not Yet Recruiting

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

NCT03258554Phase 2Completed

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT06914999Early Phase 1Recruiting

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT04162873Phase 2Terminated

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT04541355Phase 2Completed

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

NCT04140513Not ApplicableWithdrawn

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Showing all 13 trials

Research Network

Activity Timeline